Security
ATOS · ATOSSA THERAPEUTICS, INC.
ATOSNASDAQCommon stockCurrentCIK 1488039Updated Sep 27, 2026
Name history
ATOSSA GENETICS INC · through Nov 13, 2019
ATOS price & chart
Loading TradingView…
NASDAQ:ATOS on TradingView ↗About the company
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company’s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. (Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-endoxifen is not approved for any indication.
In the news
Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update News provided by Atossa Therapeutics Inc Aug 12, 2025, 08:30 ET Share this article Share to X Share this article Share to X FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-E ↗
Seeking Alpha
Atossa Therapeutics GAAP EPS of -$0.95 ↗
Atossa Therapeutics prices up to $16.5M direct offering ↗
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript ↗
SEC disclosures
ATOSSA THERAPEUTICS, INC. files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
424B5 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Show 5 more recent filings
4 filing
Financial Statements and Exhibits
Items 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 47,608,000Source | 76,444,000Source | 96,252,000Source | 123,532,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 41,299,000Source | 71,084,000Source | 88,460,000Source | 110,890,000Source |
| Assets, CurrentUSD | 45,618,000Source | 74,457,000Source | 92,219,000Source | 118,197,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,128,000Source | 1,165,000Source | 2,162,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 0Source |
| Other Assets, NoncurrentUSD | 1,990,000Source | 1,987,000Source | 2,323,000Source | 635,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,255,000Source | 4,967,000Source | 5,236,000Source | 5,568,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,550,000Source | 23,488,000Source | 22,792,000Source | 22,792,000Source |
| Additional Paid in CapitalUSD | 285,840,000Source | 261,256,000Source | 255,987,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -246,562,000Source | -211,792,000Source | -186,288,000Source | -156,194,000Source |
| Stockholders' Equity Attributable to ParentUSD | 39,353,000Source | 71,477,000Source | 91,016,000Source | 117,964,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 250,784,000Source |
| Liabilities and EquityUSD | 47,608,000Source | 76,444,000Source | 96,252,000Source | 123,532,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,255,000Source | 4,967,000Source | 5,236,000Source | 5,568,000Source |
| Accounts Payable, CurrentUSD | 4,293,000Source | 679,000Source | 806,000Source | 2,965,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,307,000Source | 919,000Source | 973,000Source | 1,059,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 8,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,646,000Source | 2,292,000Source | 4,621,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 3,614,000Source | -127,000Source | -2,159,000Source | 1,248,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,762,000Source | -21,030,000Source | -20,941,000Source | -20,760,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -23,000Source | -19,000Source | -14,000Source | -4,727,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 23,000Source | 19,000Source | 14,000Source | 27,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Payments for Repurchase of Common StockUSD | — | 0Source | 1,475,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 0Source | 3,673,000Source | -1,475,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -29,785,000Source | -17,376,000Source | -22,430,000Source | -25,487,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,646,000Source | 2,292,000Source | 4,621,000Source | 6,788,000Source |
| DepreciationUSD | 16,000Source | 17,000Source | 23,000Source | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | 0Source | -7,000Source | 0Source | -3,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 0Source | 1,710,000Source | 2,990,000Source | — |
| General and Administrative ExpenseUSD | 15,956,000Source | 13,504,000Source | 14,043,000Source | 12,608,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 2,377,000Source | 4,050,000Source | 4,343,000Source | 877,000Source |
| Net Income (Loss) Attributable to ParentUSD | -34,770,000Source | -25,504,000Source | -30,094,000Source | -26,960,000Source |
| Operating ExpensesUSD | 37,141,000Source | 27,621,000Source | 31,377,000Source | 27,691,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 15,000Source |
| Other Nonoperating Income (Expense)USD | -6,000Source | -223,000Source | -70,000Source | -146,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 0Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | 6,788,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -37,141,000Source | -27,621,000Source | -31,377,000Source | -27,691,000Source |
| Other Nonoperating Income (Expense)USD | -6,000Source | -223,000Source | -70,000Source | -146,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -34,770,000Source | -25,504,000Source | -30,094,000Source | -26,960,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -34,770,000Source | -25,504,000Source | -30,094,000Source | -26,960,000Source |
| Earnings Per Share, BasicUSD per share | -4.04Source | -0.2Source | -0.24Source | -0.21Source |
| Earnings Per Share, DilutedUSD per share | -4.04Source | -0.2Source | -0.24Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,611,321Source | 125,859,276Source | 126,081,602Source | 126,624,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,611,321Source | 125,859,276Source | 126,081,602Source | — |
| Additional Financial Items | ||||
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 0Source | 1,710,000Source | 2,990,000Source | — |
| General and Administrative ExpenseUSD | 15,956,000Source | 13,504,000Source | 14,043,000Source | 12,608,000Source |
| Investment Income, InterestUSD | 2,377,000Source | 4,050,000Source | 4,343,000Source | 877,000Source |
| Operating ExpensesUSD | 37,141,000Source | 27,621,000Source | 31,377,000Source | 27,691,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 15,000Source |
| Research and Development ExpenseUSD | 21,185,000Source | 14,117,000Source | 17,334,000Source | 15,083,000Source |
Filing attachments
atos-ex99_1.htm · 8-K · 2026-09-18
EX-99.1 2 atos-ex99_1.htm EX-99.1 Advancing (Z)-Endoxifen A potential best-in-class oral SERM/SERD for estrogen-driven diseases NASDAQ: ATOS www.atossatherapeutics.com Seattle, Washington Corporate & Investor Presentation September 2026 Exhibit 99.1 Cautionary Note Regarding Forward Looking Statements This presentation contains certain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company’s develop…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-08-07
EX-99.1 2 atos-ex99_1.htm EX-99.1 EX-99.1 Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, WASHINGTON, August 7, 2026 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended …
Read attachment ↗atos-ex4_1.htm · 8-K · 2026-06-11
EX-4.1 2 atos-ex4_1.htm EX-4.1 EX-4.1 EXHIBIT 4.1 SERIES[A]/[B] COMMON STOCK PURCHASE WARRANT ATOSSA THERAPEUTICS, INC. Warrant Shares: _______ Issue Date: June 12, 2026 Initial Exercise Date: December 12, 2026 THIS SERIES [A]/[B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 atos-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, WASHINGTON, May 8, 2026 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results and provides an update on recent corporate developments for the first quart…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-03-25
EX-99.1 2 atos-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update SEATTLE, March 25, 2026 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth quarter and year ended December 31, 2025 and provides a…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-02-11
EX-99.1 2 atos-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook SEATTLE, February 11, 2026 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph. D., Atossa Therapeutics President and Chief Executive…
Read attachment ↗